Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.51 |
| ▸ | HTR2C | P28335 | 7/20 | 0.51 |
| ▸ | PARP1 | P09874 | 6/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711148 | 0.91 | HTR2A (0.51) | HTR2AHTR2CPARP1TAAR1HTR7 | |
| SCHEMBL6712401 | 0.85 | HTR2A (0.54) | HTR2AHTR2CHTR7CHRM3 | |
| SCHEMBL6714252 | 0.85 | HTR2A (0.54) | HTR2AHTR2CPARP1CHRM3 | |
| SCHEMBL6711842 | 0.84 | HTR2A (0.51) | HTR2AHTR2CHTR7CHRM3 | |
| SCHEMBL6712009 | 0.81 | PARP1 (0.59) | HTR2AHTR2CPARP1HTR7 | |
| SCHEMBL6712393 | 0.79 | HTR2A (0.55) | HTR2AHTR2C | |
| SCHEMBL6714402 | 0.79 | HTR2C (0.58) | HTR2AHTR2CHTR7 | |
| SCHEMBL6713978 | 0.77 | HTR2A (0.71) | HTR2AHTR2C | |
| SCHEMBL6711262 | 0.77 | HTR2A (0.58) | HTR2AHTR2CHTR7 | |
| SCHEMBL6713786 | 0.77 | HTR2A (0.56) | HTR2AHTR2CCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | PHARMACIA & UPJOHN COMPANY | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | HTR1D, HTR1A, HTR1E | HTR2A 18/4885HTR2C 7/4885PARP1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.